Heteromultivalent topology-matched nanostructures as potent and broad-spectrum influenza A virus inhibitors.
Animals
Antiviral Agents
/ pharmacology
Binding Sites
Cell Membrane
/ metabolism
Dogs
Erythrocyte Membrane
/ virology
Hemagglutinin Glycoproteins, Influenza Virus
/ chemistry
Humans
Influenza A virus
/ drug effects
Influenza, Human
/ virology
Madin Darby Canine Kidney Cells
Nanoparticles
/ chemistry
Neuraminidase
/ chemistry
Protein Binding
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Virion
Virus Attachment
/ drug effects
Virus Internalization
/ drug effects
Journal
Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
17
06
2020
accepted:
09
11
2020
entrez:
1
2
2021
pubmed:
2
2
2021
medline:
17
2
2021
Statut:
epublish
Résumé
Here, we report the topology-matched design of heteromultivalent nanostructures as potent and broad-spectrum virus entry inhibitors based on the host cell membrane. Initially, we investigate the virus binding dynamics to validate the better binding performance of the heteromultivalent moieties as compared to homomultivalent ones. The heteromultivalent binding moieties are transferred to nanostructures with a bowl-like shape matching the viral spherical surface. Unlike the conventional homomultivalent inhibitors, the heteromultivalent ones exhibit a half maximal inhibitory concentration of 32.4 ± 13.7 μg/ml due to the synergistic multivalent effects and the topology-matched shape. At a dose without causing cellular toxicity, >99.99% reduction of virus propagation has been achieved. Since multiple binding sites have also been identified on the S protein of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), we envision that the use of heteromultivalent nanostructures may also be applied to develop a potent inhibitor to prevent coronavirus infection.
Identifiants
pubmed: 33523846
pii: 7/1/eabd3803
doi: 10.1126/sciadv.abd3803
pmc: PMC7775783
pii:
doi:
Substances chimiques
Antiviral Agents
0
H1N1 virus hemagglutinin
0
Hemagglutinin Glycoproteins, Influenza Virus
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Neuraminidase
EC 3.2.1.18
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).
Références
Nat Nanotechnol. 2020 May;15(5):373-379
pubmed: 32231271
Virology. 2019 Jan 15;527:132-140
pubmed: 30503907
Science. 2019 Mar 8;363(6431):
pubmed: 30846569
J Am Chem Soc. 2015 Feb 25;137(7):2572-9
pubmed: 25623606
J Am Chem Soc. 2018 Aug 8;140(31):9891-9898
pubmed: 30014698
Rev Med Virol. 2002 May-Jun;12(3):159-66
pubmed: 11987141
Trends Microbiol. 2020 Jan;28(1):57-67
pubmed: 31629602
Angew Chem Int Ed Engl. 2017 May 15;56(21):5931-5936
pubmed: 28444849
Nano Lett. 2020 Jul 8;20(7):5570-5574
pubmed: 32551679
Adv Mater. 2016 Nov;28(43):9581-9588
pubmed: 27628433
J Virol. 2009 Oct;83(20):10366-73
pubmed: 19641000
Nano Lett. 2019 Mar 13;19(3):1875-1882
pubmed: 30719917
J Am Chem Soc. 2020 Jul 15;142(28):12181-12192
pubmed: 32538085
Surf Sci Rep. 2006 Nov 15;61(10):429-444
pubmed: 32287559
J Am Chem Soc. 2019 Oct 16;141(41):16303-16311
pubmed: 31533424
Anal Chem. 2015 Sep 15;87(18):9194-203
pubmed: 26268463
Cell Res. 2020 Apr;30(4):343-355
pubmed: 32231345
Euro Surveill. 2017 Jan 19;22(3):
pubmed: 28128091
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Biomaterials. 2017 Sep;138:22-34
pubmed: 28550754
Science. 2019 Oct 25;366(6464):499-504
pubmed: 31649200
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Phys Rev Lett. 2011 Oct 28;107(18):188103
pubmed: 22107678
Nat Nanotechnol. 2017 Jan;12(1):48-54
pubmed: 27775724
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Adv Mater. 2018 Jun;30(23):e1706759
pubmed: 29582476
Cell Microbiol. 2020 May;22(5):e13170
pubmed: 31990121
Chem Sci. 2019 Nov 14;11(1):27-36
pubmed: 32153750
J Am Chem Soc. 2019 Sep 25;141(38):15403-15412
pubmed: 31469952
Sci Adv. 2019 Oct 23;5(10):eaaw6870
pubmed: 31681841
Elife. 2019 May 14;8:
pubmed: 31084711
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Science. 2010 Jun 4;328(5983):1272-5
pubmed: 20522774
J Am Chem Soc. 2014 Jan 15;136(2):783-8
pubmed: 24377426
Annu Rev Pathol. 2008;3:499-522
pubmed: 18039138
Theranostics. 2016 Apr 28;6(7):1004-11
pubmed: 27217833
Science. 2018 Nov 2;362(6414):598-602
pubmed: 30385580
Trends Microbiol. 2019 Jun;27(6):477-479
pubmed: 30930001
PLoS One. 2016 Oct 3;11(10):e0163437
pubmed: 27695072
Science. 2020 Jun 12;368(6496):1274-1278
pubmed: 32404477
Vaccine. 2007 Sep 28;25(39-40):6852-62
pubmed: 17719149
Sci Adv. 2019 Apr 10;5(4):eaav4580
pubmed: 30989115
Nat Nanotechnol. 2013 Dec;8(12):933-8
pubmed: 24292514
Nat Nanotechnol. 2013 May;8(5):336-40
pubmed: 23584215
Cell. 2018 Apr 5;173(2):417-429.e10
pubmed: 29625056
J Am Chem Soc. 2017 May 3;139(17):6018-6025
pubmed: 28394600
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9280-5
pubmed: 12883000
Sci Adv. 2020 Apr 15;6(16):eaay9035
pubmed: 32490199
Nat Chem. 2016 Jan;8(1):50-7
pubmed: 27055288
JAMA. 2004 Sep 15;292(11):1333-40
pubmed: 15367555
N Engl J Med. 1999 Oct 28;341(18):1336-43
pubmed: 10536125
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Antivir Ther. 2017;22(6):515-522
pubmed: 28205506